CStone Pharmaceuticals (HKG:2616) entered into a strategic commercial collaboration with UAE-based Pharmalink Store, a Thursday bourse filing said.
Under the license and commercialization agreement, Pharmalink will gain the commercial rights for tumor drug sugemalimab in the Middle East and North Africa (MENA) Region in return for upfront and regulatory milestone payments to CStone.
CStone Pharmaceuticals is responsible for the supply of the drug will also be entitled to royalties on the net sales of sugemalimab in the MENA Region and South Africa.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.